tetano
Editor, Senior Moderator
Eur J Med Chem
. 2024 Feb 6:268:116202.
doi: 10.1016/j.ejmech.2024.116202. Online ahead of print. Design, synthesis, and biological evaluation of first-in-class indomethacin-based PROTACs degrading SARS-CoV-2 main protease and with broad-spectrum antiviral activity
Jenny Desantis[SUP] 1 [/SUP], Alessandro Bazzacco[SUP] 2 [/SUP], Michela Eleuteri[SUP] 1 [/SUP], Sara Tuci[SUP] 2 [/SUP], Elisa Bianconi[SUP] 3 [/SUP], Antonio Macchiarulo[SUP] 3 [/SUP], Beatrice Mercorelli[SUP] 4 [/SUP], Arianna Loregian[SUP] 5 [/SUP], Laura Goracci[SUP] 6 [/SUP]
Affiliations
To date, Proteolysis Targeting Chimera (PROTAC) technology has been successfully applied to mediate proteasomal-induced degradation of several pharmaceutical targets mainly related to oncology, immune disorders, and neurodegenerative diseases. On the other hand, its exploitation in the field of antiviral drug discovery is still in its infancy. Recently, we described two indomethacin (INM)-based PROTACs displaying broad-spectrum antiviral activity against coronaviruses. Here, we report the design, synthesis, and characterization of a novel series of INM-based PROTACs that recruit either Von-Hippel Lindau (VHL) or cereblon (CRBN) E3 ligases. The panel of INM-based PROTACs was also enlarged by varying the linker moiety. The antiviral activity resulted very susceptible to this modification, particularly for PROTACs hijacking VHL as E3 ligase, with one piperazine-based compound (PROTAC 6) showing potent anti-SARS-CoV-2 activity in infected human lung cells. Interestingly, degradation assays in both uninfected and virus-infected cells with the most promising PROTACs emerged so far (PROTACs 5 and 6) demonstrated that INM-PROTACs do not degrade human PGES-2 protein, as initially hypothesized, but induce the concentration-dependent degradation of SARS-CoV-2 main protease (M[SUP]pro[/SUP]) both in M[SUP]pro[/SUP]-transfected and in SARS-CoV-2-infected cells. Importantly, thanks to the target degradation, INM-PROTACs exhibited a considerable enhancement in antiviral activity with respect to indomethacin, with EC[SUB]50[/SUB] values in the low-micromolar/nanomolar range. Finally, kinetic solubility as well as metabolic and chemical stability were measured for PROTACs 5 and 6. Altogether, the identification of INM-based PROTACs as the first class of SARS-CoV-2 M[SUP]pro[/SUP] degraders demonstrating activity also in SARS-CoV-2-infected cells represents a significant advance in the development of effective, broad-spectrum anti-coronavirus strategies.
Keywords: Antiviral; Main protease (M(pro)); PROTAC; SARS-CoV-2; Targeted protein degradation.
. 2024 Feb 6:268:116202.
doi: 10.1016/j.ejmech.2024.116202. Online ahead of print. Design, synthesis, and biological evaluation of first-in-class indomethacin-based PROTACs degrading SARS-CoV-2 main protease and with broad-spectrum antiviral activity
Jenny Desantis[SUP] 1 [/SUP], Alessandro Bazzacco[SUP] 2 [/SUP], Michela Eleuteri[SUP] 1 [/SUP], Sara Tuci[SUP] 2 [/SUP], Elisa Bianconi[SUP] 3 [/SUP], Antonio Macchiarulo[SUP] 3 [/SUP], Beatrice Mercorelli[SUP] 4 [/SUP], Arianna Loregian[SUP] 5 [/SUP], Laura Goracci[SUP] 6 [/SUP]
Affiliations
- PMID: 38394929
- DOI: 10.1016/j.ejmech.2024.116202
To date, Proteolysis Targeting Chimera (PROTAC) technology has been successfully applied to mediate proteasomal-induced degradation of several pharmaceutical targets mainly related to oncology, immune disorders, and neurodegenerative diseases. On the other hand, its exploitation in the field of antiviral drug discovery is still in its infancy. Recently, we described two indomethacin (INM)-based PROTACs displaying broad-spectrum antiviral activity against coronaviruses. Here, we report the design, synthesis, and characterization of a novel series of INM-based PROTACs that recruit either Von-Hippel Lindau (VHL) or cereblon (CRBN) E3 ligases. The panel of INM-based PROTACs was also enlarged by varying the linker moiety. The antiviral activity resulted very susceptible to this modification, particularly for PROTACs hijacking VHL as E3 ligase, with one piperazine-based compound (PROTAC 6) showing potent anti-SARS-CoV-2 activity in infected human lung cells. Interestingly, degradation assays in both uninfected and virus-infected cells with the most promising PROTACs emerged so far (PROTACs 5 and 6) demonstrated that INM-PROTACs do not degrade human PGES-2 protein, as initially hypothesized, but induce the concentration-dependent degradation of SARS-CoV-2 main protease (M[SUP]pro[/SUP]) both in M[SUP]pro[/SUP]-transfected and in SARS-CoV-2-infected cells. Importantly, thanks to the target degradation, INM-PROTACs exhibited a considerable enhancement in antiviral activity with respect to indomethacin, with EC[SUB]50[/SUB] values in the low-micromolar/nanomolar range. Finally, kinetic solubility as well as metabolic and chemical stability were measured for PROTACs 5 and 6. Altogether, the identification of INM-based PROTACs as the first class of SARS-CoV-2 M[SUP]pro[/SUP] degraders demonstrating activity also in SARS-CoV-2-infected cells represents a significant advance in the development of effective, broad-spectrum anti-coronavirus strategies.
Keywords: Antiviral; Main protease (M(pro)); PROTAC; SARS-CoV-2; Targeted protein degradation.